Executive Summary
Cell MedX Corp (CMXC) QQ3 2025 presents a deteriorating profitability and liquidity backdrop with no revenue disclosed for the period. The reported net loss of $140,537 and an EPS of -0.0071 accompany a steep operating expense profile (R&D $493, G&A $32,847; total operating expenses $131,086) and another $97,746 of other expenses, culminating in a negative income before tax of -$140,537. Operating cash flow was -$29,979 for the quarter, yielding a free cash flow of -$29,976 and a closing cash balance of $6,678. The balance sheet reveals an extreme imbalance: total assets of $17,110 against total liabilities of $1,087,325 and stockholders’ equity of -$1,070,215, with an ultra-tight liquidity footprint (current/quick/cash ratios all at 0.0215). These dynamics imply acute runway risk and a heavy reliance on external funding to sustain operations.
The available data shows no disclosed revenue and no EBITDA figures, making it difficult to assess operating leverage or unit economics. YoY and QoQ metrics show meaningful deterioration in net income (-217.14% YoY) and EPS (-344.83% YoY; -1.43% QoQ) in a quarter already characterized by minimal cost visibility. Management commentary or earnings-call transcript data are not provided in the dataset, limiting the ability to quote management themes or validate forward-looking statements. In this context, the investment risk is high, and near-term catalysts would hinge on financing developments, strategic partnerships, or explicit monetization plans for the eBalance platform (Professional and Home System) referenced in the company profile. The overall prognosis hinges on solvency actions (funding, restructuring, or asset monetization) and a credible revenue-generation plan.
Key Performance Indicators
QoQ: -0.74% | YoY:-217.14%
QoQ: -1.43% | YoY:-344.83%
Key Insights
Revenue: Not disclosed for QQ3 2025.
Net income: -$140,537; YoY change: -217.14%; QoQ change: -0.74%.
EPS: -$0.0071; YoY: -344.83%; QoQ: -1.43%.
R&D expenses: $493.00; General and Administrative expenses: $32,847.00; Selling/SG&A: $32,847.00 (aggregated G&A).
Other expenses: $97,746.00; Operating expenses: $131,086.00.
Income before tax: -$140,537.00; Net income: -$140,537.00.
Cash flow from operations: -$29,979.00; Capex: $3.00; Free cash flow: -$29,976.00.
Cash at end of period: $...
Financial Highlights
Revenue: Not disclosed for QQ3 2025.
Net income: -$140,537; YoY change: -217.14%; QoQ change: -0.74%.
EPS: -$0.0071; YoY: -344.83%; QoQ: -1.43%.
R&D expenses: $493.00; General and Administrative expenses: $32,847.00; Selling/SG&A: $32,847.00 (aggregated G&A).
Other expenses: $97,746.00; Operating expenses: $131,086.00.
Income before tax: -$140,537.00; Net income: -$140,537.00.
Cash flow from operations: -$29,979.00; Capex: $3.00; Free cash flow: -$29,976.00.
Cash at end of period: $6,678.00; Cash at beginning: $20,552.00; Net change in cash: -$13,874.00.
Total assets: $17,110.00; Total liabilities: $1,087,325.00; Stockholders’ equity: -$1,070,215.00.
Current ratio: 0.0215; Quick ratio: 0.0215; Cash ratio: 0.0215.
Return on assets: -8.21%; Return on equity: 0.131%; Net income margin: 0 (not disclosed); Gross/Operating margins: 0 (not disclosed).
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Net Income |
-140.54K |
-217.14% |
-0.74% |
| EPS |
-0.01 |
-344.83% |
-1.43% |
Key Financial Ratios
operatingCashFlowPerShare
$-0
priceEarningsRatio
-14.45
Management Commentary
Note: The dataset provides an earnings transcript array but contains no transcript content for QQ3 2025. As such, there are no management quotes or theme insights to extract at this time.
Forward Guidance
No explicit management guidance is provided in the QQ3 2025 dataset. Given the current liquidity strain and absence of revenue, near-term guidance would be pivotal for investor assessment but is not visible here. If management does issue forward-looking targets, those would need to address: (1) revenue generation strategy for eBalance Pro/Home systems, (2) cost-control or restructuring steps to restore operating leverage, and (3) liquidity runway and funding plan. Absent a credible monetization path and external financing, the forward outlook remains highly uncertain. Key factors to monitor include any announced financing rounds, licensing or strategic partnerships, regulatory milestones (if applicable to the device platforms), and progress toward revenue realization from the eBalance ecosystem.